Found an article called:
Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment
by Harrys A. Torres, Jean-Nicolas Vauthey, Minas Platon Economides, Parag Mahale, Ahmed Kaseb
on the internet: www.journal-of-hepatology.eu/article/S01...(16)30248-3/fulltext
We read with interest the article by Reig et al.  and applaud their pharmacovigilance efforts. However, because we work in a major cancer center in the United States, we are concerned about the consequences of the authors’ assumption that the use of direct-acting antivirals (DAAs) may induce hepatocellular carcinoma (HCC) relapse. This can affect not only the already cumbersome approval of DAAs for hepatitis C virus (HCV)-infected patients with HCC but also preclude patients with other cancers or HCV-associated malignancies (e.g., non-Hodgkin lymphomas) from receiving antiviral treatment associated with improved virologic, hepatic, and oncologic outcomes [2,3].
a) I hope the caution needed after the April 2016 stuff came to light does not lead to throwing the DAA baby out with the bath water.
b) if you had a HCC, don't think you can forget about it.
On another note,there is another I found:
Direct antiviral agents and risk for HCC early recurrence: much ado about nothing
by Calogero Cammà, Giuseppe Cabibbo, Antonio Craxì. Ref: www.journal-of-hepatology.eu/article/S01...(16)30248-3/fulltext
My assessment: Keep your head down around researchers when they are in 'peer review' mode!
Nothing about HCC seems easy.
GT3a 1990 Failed Inter 1998, comb in 2000. HCC 2012
Started 24/52 Sof/Dac 27th October 2015.
1. Bloods 2 October 2015: AST - 165 (20-40), ALT - 265 (5-40), GGT 189 (5-50)
2, Bloods 20 November 2015: ALT etc normal; VL 19
3. Bloods 8 January 2016: AST - 40, ALT - 59, GGT 48 VL RNA UND
4. EOT 12 April 2016 - blood tests: all is well, CT scan: okay
5. AFP 11 June 2016: 4 ref< 11
6. VL July 2016: DET
7. Oct16 start treat - June17 UND
8. Jun 18, lfts okay, platelets a bit low.